Biopolymer zein nanoparticles loaded with Moringa Oleifera extract for improved wound healing activity: Development, Qbd based optimization and in vivo study.

Recently, nanobiomaterials have been explored for improved biological activities and value addition to the herbal extracts. Zein is a natural biopolymer with excellent pharmaceutical characteristics for topical applications. Moringa oleifera plant possesses large number of phytopharmaceuticals and its leaves are used in wound healing since ancient time. In this study, we studied first time, encapsulation of Moringa oleifera leaves aqueous extract into zein nanoparticles which are developed and optimized using quality by design approach. Moringa oleifera leaves aqueous extract was characterized by FTIR and total phenolic content determination. Moringa oleifera leaves aqueous extract loaded zein nanoparticles were systematically characterized for particle size, PDI, zeta potential, transmission electron microscopy and loading capacity. Further, a gel having optimized formulation for topical application was prepared and characterized for pH, spreadability, extrudability and storage stability. The so developed formulation were tested for wound healing activities on animals and results clearly indicated significant activity (p < 0.05) in case of Moringa oleifera leaves aqueous extract loaded zein nanoparticles formulation than control and relatively improved wound healing than Moringa oleifera leaves aqueous extract only loaded gel . This study opens up new possibilities in exploring zein nanoparticles for herbal extract based therapeutic applications.

Development of Nanomedicines and Nano-Similars: Recent Advances in Regulatory Landscape.

BACKGROUND: Nanopharmaceuticals serve as emerging forms of modern medicines, which include nanomedicines, nanosimilars, nanotheranostics, nanodevices, and many more. In the last two decades, a large number of nano-based products have reached the market and are being used clinically. OBJECTIVES: Unlike conventional pharmaceutical products, nanopharmaceuticals behave differently both in vitro and in vivo, and therefore, the development of their generic versions needs special attention to replicate the similar drug release pattern leading to an identical therapeutic outcome. Further, drug-device combinations and 3D products are the latest advancements in precision medicine delivery and development. METHODS: The regulatory guidelines for these products are being framed at many stages by various regulatory agencies like USFDA/EMA and still are in infancy at the moment if we look at wider perspectives and applications of nanomedicine. RESULTS: For a formulation scientist, it is much needed that well-explained and directive guidelines should be made available before leading to the development of the generic versions of these nano-cargos. CONCLUSION: Here, in this review, we have summarized the silent features of the regulatory perspectives related to nanotechnology based next generation therapeutics and diagnostics.

Nanotheranostics for Cancer Therapy and Detection: State of the Art.

Nanotheranostics, an approach of combining both diagnosis and therapy, is one of the latest advances in cancer therapy particularly. Nanocarriers designed and derived from inorganic materials such as like gold nanoparticles, silica nanoparticles, magnetic nanoparticles and carbon nanotubes have been explored for tremendous applications in this area. Similarly, nanoparticles composed of some organic material alone or in combination with inorganic nano-cargos have been developed pre-clinically and possess excellent features desired. Photothermal therapy, MRI, simultaneous imaging and delivery, and combination chemotherapy with a diagnosis are a few of the known methods exploring cancer therapy and detection at organ/tissue/molecular/sub-cellular level. This review comprises an overview of the recent reports meant for nano theranostics purposes. Targeted cancer nanotheranostics have been included for understating tumor micro-environment or cell-specific targeting approach employed. A brief account of various strategies is also included for the readers highlighting the mechanism of cancer therapy.

Solid lipid nanoparticles: a review on recent perspectives and patents.

Introduction: Solid lipid nanoparticles (SLNs) are solid core lipid nanocarriers, which can hold both hydrophilic and hydrophobic drugs. They can be made up of biocompatible ingredients and therefore are one of the preferred choices for drug delivery. Surface modifications of SLNs may further provide unique features to them like mucoadhesiveness or targeting capability.Areas covered: In this review, the authors have covered areas from the basic introduction of SLNs to its applications in controlled drug delivery. More specifically, the authors have covered patents disclosed related to the SLNs for the period 2014-2019; however, a summary of patents of 2008-2013 is also included.Expert opinion: SLNs have been explored for development of compositions/formulations with improved therapeutics or cosmetic applications or for nutraceutical applications. Targeted SLNs compositions have been patented as evidenced from the literature; however, not such types of enough SLNs formulations have been claimed for the same.